What Does Wall Street Think About Merck & Co. (MRK)?

Merck & Co., Inc. (NYSE:MRK) is one of the best medical stocks to buy now. On September 26, Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Co., Inc. (NYSE:MRK). Similarly, Roth MKM also assigned a Hold rating to the stock on September 17 with a $90 price target.

In another report released on September 16, Berenberg Bank also downgraded Merck & Co., Inc. (NYSE:MRK) to a Hold, bringing the price target down to $90 from $100.

Merck & Co., Inc. (NYSE:MRK) has an analyst consensus of Moderate Buy, and the stock’s median price target of $82.78 implies an upside of 18.39% from current levels.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.